MA38472B1 - Composé peptidique - Google Patents
Composé peptidiqueInfo
- Publication number
- MA38472B1 MA38472B1 MA38472A MA38472A MA38472B1 MA 38472 B1 MA38472 B1 MA 38472B1 MA 38472 A MA38472 A MA 38472A MA 38472 A MA38472 A MA 38472A MA 38472 B1 MA38472 B1 MA 38472B1
- Authority
- MA
- Morocco
- Prior art keywords
- peptide compound
- relates
- medicament
- receptors
- peptide
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 4
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 239000003814 drug Substances 0.000 abstract 2
- 102000007446 Glucagon-Like Peptide-1 Receptor Human genes 0.000 abstract 1
- 108010086246 Glucagon-Like Peptide-1 Receptor Proteins 0.000 abstract 1
- 230000003213 activating effect Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La présente invention concerne un nouveau composé peptidique ayant pour effet d'activer les récepteurs au glp-1 et les récepteurs au gip, ainsi que l'utilisation dudit composé peptidique en tant que médicament. L'invention concerne, plus précisément, un peptide contenant une séquence partielle représentée par la formule (i), ou un sel de celui-ci et un médicament en contenant. P
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2013111893 | 2013-05-28 | ||
| PCT/JP2014/002772 WO2014192284A1 (fr) | 2013-05-28 | 2014-05-27 | Composé peptidique |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA38472A1 MA38472A1 (fr) | 2018-01-31 |
| MA38472B1 true MA38472B1 (fr) | 2018-09-28 |
Family
ID=50942304
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA38472A MA38472B1 (fr) | 2013-05-28 | 2014-05-27 | Composé peptidique |
Country Status (35)
| Country | Link |
|---|---|
| US (2) | US10087229B2 (fr) |
| EP (1) | EP3004155B1 (fr) |
| JP (2) | JP6429799B2 (fr) |
| KR (1) | KR102229051B1 (fr) |
| CN (1) | CN105209485B (fr) |
| AP (1) | AP2015008781A0 (fr) |
| AR (1) | AR096440A1 (fr) |
| AU (1) | AU2014272500B2 (fr) |
| CA (1) | CA2908581C (fr) |
| CL (1) | CL2015003031A1 (fr) |
| CY (1) | CY1124790T1 (fr) |
| DK (1) | DK3004155T3 (fr) |
| DO (1) | DOP2015000261A (fr) |
| EA (2) | EA035813B1 (fr) |
| EC (1) | ECSP15044389A (fr) |
| ES (1) | ES2900744T3 (fr) |
| GE (1) | GEP201706762B (fr) |
| HR (1) | HRP20212014T1 (fr) |
| HU (1) | HUE057361T2 (fr) |
| IL (1) | IL242005B (fr) |
| LT (1) | LT3004155T (fr) |
| MA (1) | MA38472B1 (fr) |
| MX (2) | MX373436B (fr) |
| MY (1) | MY172744A (fr) |
| PE (1) | PE20151770A1 (fr) |
| PH (1) | PH12015502391B1 (fr) |
| PL (1) | PL3004155T3 (fr) |
| PT (1) | PT3004155T (fr) |
| SG (1) | SG11201507934PA (fr) |
| SI (1) | SI3004155T1 (fr) |
| TN (1) | TN2015000451A1 (fr) |
| TW (1) | TWI638831B (fr) |
| UA (1) | UA118558C2 (fr) |
| UY (1) | UY35589A (fr) |
| WO (1) | WO2014192284A1 (fr) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3004155T3 (da) | 2013-05-28 | 2022-01-03 | Takeda Pharmaceuticals Co | Peptidforbindelse |
| AR103242A1 (es) * | 2015-01-09 | 2017-04-26 | Lilly Co Eli | Compuestos co-agonistas de gip y glp-1 |
| CN104846061A (zh) * | 2015-05-07 | 2015-08-19 | 中国药科大学 | 一种glp-1受体激动剂的受体亲和力测定方法 |
| CN105388239B (zh) * | 2015-12-18 | 2018-01-05 | 兆科药业(合肥)有限公司 | 一种多肽固相合成的监测方法 |
| EP3467106B1 (fr) | 2016-05-24 | 2025-07-09 | Takeda Pharmaceutical Company Limited | Composé peptidique |
| EP3551202B1 (fr) | 2016-12-06 | 2024-01-24 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Procédés d'amélioration de l'efficacité de médicaments à base d'incrétine chez les sujets en ayant besoin |
| JOP20190211A1 (ar) * | 2017-03-31 | 2019-09-15 | Takeda Pharmaceuticals Co | ببتيد منشط لمستقبل gip |
| WO2019140030A1 (fr) | 2018-01-12 | 2019-07-18 | Eli Lilly And Company | Polythérapie |
| US11911445B2 (en) * | 2018-01-23 | 2024-02-27 | Gila Therapeutics, Inc. | Peptide YY pharmaceutical formulations, compositions, and methods |
| PE20210473A1 (es) | 2018-05-04 | 2021-03-08 | Novo Nordisk As | Derivados de gip y usos de estos |
| AU2019309798A1 (en) * | 2018-07-23 | 2021-02-11 | Eli Lilly And Company | Method of using a GIP/GLP1 co-agonist for diabetes |
| CN110818771B (zh) * | 2018-08-14 | 2023-01-17 | 陈铭 | 使用氨基酸离子液体的羰基硫介导多肽合成 |
| EP3856768A2 (fr) | 2018-09-24 | 2021-08-04 | Takeda Pharmaceutical Company Limited | Composés peptidiques agonistes du récepteur du gip et leurs utilisations |
| US20220016215A1 (en) * | 2018-09-24 | 2022-01-20 | Takeda Phaarmaceutical Company Limited | Gip receptor agonist peptide compounds and uses thereof |
| WO2021034815A1 (fr) * | 2019-08-19 | 2021-02-25 | Eli Lilly And Company | Procédés de fabrication d'analogues d'incrétine |
| JP7761557B2 (ja) | 2019-10-04 | 2025-10-28 | ハンミ ファーマシューティカル カンパニー リミテッド | グルカゴン、及びglp-1受容体及びgip受容体二重アゴニストを含む組成物及びその治療学的使用 |
| CN110684082B (zh) | 2019-10-08 | 2021-12-10 | 江苏诺泰澳赛诺生物制药股份有限公司 | Gip和glp-1双激动多肽化合物及药学上可接受的盐与用途 |
| IL296592A (en) * | 2020-03-25 | 2022-11-01 | Takeda Pharmaceuticals Co | Qd dosing of gip receptor agonist peptide compounds and uses thereof |
| EP4171662A1 (fr) * | 2020-03-31 | 2023-05-03 | Antaros Medical AB | Agonistes sélectifs du récepteur de gip comprenant une fraction chélatante à des fins d'imagerie et de thérapie |
| JP2023534130A (ja) | 2020-07-22 | 2023-08-08 | ノヴォ ノルディスク アー/エス | Glp-1受容体およびgip受容体共作動薬 |
| AU2021312323A1 (en) | 2020-07-22 | 2023-02-02 | Novo Nordisk A/S | Co-agonists at GLP-1 and GIP receptors suitable for oral delivery |
| US12029718B2 (en) | 2021-11-09 | 2024-07-09 | Cct Sciences, Llc | Process for production of essentially pure delta-9-tetrahydrocannabinol |
| WO2022253202A1 (fr) | 2021-06-01 | 2022-12-08 | 南京知和医药科技有限公司 | Dérivé polypeptidique ayant un effet d'activation à double cible de glp-1r et de gipr, procédé de préparation associé et son utilisation |
| TW202330584A (zh) | 2022-01-20 | 2023-08-01 | 丹麥商諾佛 儂迪克股份有限公司 | 前藥及其用途 |
| CN117229364A (zh) * | 2022-06-06 | 2023-12-15 | 成都奥达生物科技有限公司 | 一种gip-glp-1双激动剂化合物 |
| CN117402219B (zh) * | 2022-07-13 | 2024-07-30 | 杭州中美华东制药有限公司 | Glp-1/gip双激动剂及其制备方法和用途 |
| JP2025523981A (ja) * | 2022-07-20 | 2025-07-25 | バイキング・セラピューティクス・インコーポレイテッド | 代謝及び肝臓障害の処置のための医薬製剤及び方法 |
| CN119894921A (zh) | 2022-09-15 | 2025-04-25 | 伊莱利利公司 | Gip和glp-1双重激动剂化合物 |
| CN121001710A (zh) | 2022-12-30 | 2025-11-21 | 阿尔吉法玛公司 | 提高口服多肽治疗剂的全身生物利用度的组合物和方法 |
| WO2024165571A2 (fr) | 2023-02-06 | 2024-08-15 | E-Therapeutics Plc | Inhibiteurs d'expression et/ou de fonction |
| EP4714434A1 (fr) | 2023-05-19 | 2026-03-25 | Aulbio Co., Ltd. | Microsphère comprenant du tirzépatide, son procédé de préparation, et composition pharmaceutique la comprenant |
| EP4724472A2 (fr) | 2023-06-09 | 2026-04-15 | Sun Pharmaceutical Industries Limited | Nouveaux agonistes du récepteur double glp-1/gip et glp-1/gcg |
| CN121443305A (zh) | 2023-06-30 | 2026-01-30 | 西兰制药公司 | 组合治疗 |
| AR134436A1 (es) * | 2023-11-22 | 2026-01-14 | Hangzhou Zhongmeihuadong Pharmaceutical Co Ltd | Uso de un agonista dual glp-1r / gipr en la fabricación de un medicamento veterinario |
| TWI926512B (zh) | 2023-11-30 | 2026-05-21 | 丹麥商諾佛 儂迪克股份有限公司 | Glp-1、gip及澱粉素受體之三重促效劑 |
| WO2025125576A2 (fr) | 2023-12-15 | 2025-06-19 | E-Therapeutics Plc | Inhibiteurs d'expression et/ou de fonction |
| AU2024408289A1 (en) | 2023-12-22 | 2026-08-06 | Tangram Therapeutics Plc | Inhibitors of expression and/or function |
| EP4686757A1 (fr) | 2024-07-31 | 2026-02-04 | e-therapeutics PLC | Inhibiteurs d expression et/ou de fonction |
| CN122555713A (zh) * | 2023-12-29 | 2026-08-11 | 杭州中美华东制药有限公司 | Glp-1/gip双激动剂的固相合成方法 |
| WO2025149039A1 (fr) * | 2024-01-12 | 2025-07-17 | 杭州中美华东制药有限公司 | Composition pharmaceutique d'agoniste double de glp-1/gip à action prolongée |
| CN122535418A (zh) * | 2024-01-12 | 2026-08-07 | 杭州中美华东制药有限公司 | 长效glp-1/gip双激动剂的鼻腔递送药物组合物 |
| WO2025196502A1 (fr) | 2024-03-20 | 2025-09-25 | North Carolina Agricultural & Technical State University | Inhibiteurs de choline kinase utilisés en tant que traitement thérapeutique contre l'obésité |
| KR102991397B1 (ko) | 2024-11-29 | 2026-07-21 | 노보 노르디스크 에이/에스 | Glp-1, gip, 및 아밀린 수용체의 삼중작용제 및 이의 용도 |
| GB202418179D0 (en) | 2024-12-11 | 2025-01-22 | Algipharma As | Compositions and methods |
| GB202418172D0 (en) | 2024-12-11 | 2025-01-22 | Algipharma As | Compositions and methods |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA65549C2 (uk) | 1996-11-05 | 2004-04-15 | Елі Ліллі Енд Компані | Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція |
| EP0941114B1 (fr) | 1996-11-12 | 2005-02-23 | Novo Nordisk A/S | Utilisation de peptides glp-1 |
| WO1999047161A1 (fr) | 1998-03-19 | 1999-09-23 | Bionebraska, Inc. | Regulation de l'appetit chez les humains par un compose se liant a un recepteur de peptide de type glucagon |
| AU5027299A (en) | 1998-07-31 | 2000-02-28 | Novo Nordisk A/S | Use of glp-1 and analogues for preventing type ii diabetes |
| PL208751B1 (pl) | 1998-12-07 | 2011-06-30 | Sod Conseils Rech Applic | Związki stanowiące analogi GLP-1, kompozycje zawierające takie związki oraz zastosowanie takich związków |
| WO2001087341A1 (fr) | 2000-05-16 | 2001-11-22 | Sanwa Kagaku Kenkyusho Co.,Ltd. | Agents permettant de prevenir ou d'ameliorer l'insulino-resistance et/ou l'obesite |
| MXPA04012497A (es) | 2002-07-04 | 2005-07-14 | Zealand Pharma As | Glp-1 y metodos para tratar la diabetes. |
| EP1711523B1 (fr) | 2003-12-16 | 2012-10-10 | Ipsen Pharma | Analogues du glp-1 |
| WO2006049681A2 (fr) | 2004-08-30 | 2006-05-11 | Bayer Pharmaceuticals Corporation | Agonistes recepteur y2 neuropeptidiques selectifs |
| CA2597649A1 (fr) | 2005-02-11 | 2006-08-17 | Amylin Pharmaceuticals, Inc. | Analogues de gip et polypeptides hybrides de gip aux proprietes selectionnables |
| WO2006136374A2 (fr) | 2005-06-20 | 2006-12-28 | Develogen Aktiengesellschaft | Utilisation du gip et/ou de la vitamine d3 et d'analogues correspondants pour ameliorer la differenciation de cellules souches ou progenitrices en cellules productrices d'insuline |
| JP2009542813A (ja) | 2006-07-11 | 2009-12-03 | ハルクネスス プハルマセウティカルス,インコーポレイテッド | 飽食因子を使用して肥満を治療する方法 |
| JP5399244B2 (ja) | 2006-08-17 | 2014-01-29 | アミリン・ファーマシューティカルズ,リミテッド・ライアビリティ・カンパニー | 選択可能な特性を持つdpp−iv耐性gipハイブリッドポリペプチド |
| JO2945B1 (en) | 2006-09-13 | 2016-03-15 | سميث كلاين بيتشام كوربوريشن | Methods of giving prolonged hypoglycemic agents |
| EP1972349A1 (fr) | 2007-03-21 | 2008-09-24 | Biocompatibles UK Limited | Peptides à fusion GLP-1 associée à un/plusieurs polymères, leur production et utilisation |
| WO2009067268A1 (fr) | 2007-11-23 | 2009-05-28 | Michael Rothkopf | Procédés d'amplification de la résolution d'un diabète |
| ES2558842T3 (es) | 2008-06-17 | 2016-02-09 | Indiana University Research And Technology Corporation | Agonistas mixtos a base de GIP para el tratamiento de trastornos metabólicos y obesidad |
| KR20130133103A (ko) | 2008-08-07 | 2013-12-05 | 입센 파마 에스.에이.에스 | N-말단이 변형된 포도당 의존적인 인슐린 분비 자극성 폴리펩타이드(gip)의 유사체 |
| HUE031900T2 (en) | 2008-12-10 | 2017-08-28 | Glaxosmithkline Llc | Pharmaceutical compositions containing Albiglutide |
| WO2010148089A1 (fr) | 2009-06-16 | 2010-12-23 | Indiana University Research And Technology Corporation | Composés de glucagon actifs sur le récepteur gip |
| EP2450374B9 (fr) | 2009-07-02 | 2016-11-23 | Takeda Pharmaceutical Company Limited | Peptide et son utilisation |
| KR20120123443A (ko) | 2010-01-27 | 2012-11-08 | 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 | 대사 장애 및 비만 치료용 글루카곤 길항제-gip 항진제 콘쥬게이트 |
| AR080592A1 (es) | 2010-03-26 | 2012-04-18 | Lilly Co Eli | Peptido con actividad para el gip-r y glp-1-r, formulacion famaceutica que lo comprende, su uso para preparar un medicamento util para el tratamiento de diabetes mellitus y para inducir la perdida de peso |
| RU2013133803A (ru) | 2010-12-22 | 2015-01-27 | Маркадиа Байотек, Инк. | Способы лечения метаболических нарушений и ожирения при помощи пептидов на основе глюкагона, активных по отношению к рецепторам гип и гпп |
| US9790262B2 (en) | 2011-04-05 | 2017-10-17 | Longevity Biotech, Inc. | Compositions comprising glucagon analogs and methods of making and using the same |
| KR102002783B1 (ko) * | 2011-06-10 | 2019-07-24 | 베이징 한미 파마슈티컬 컴퍼니 리미티드 | 포도당 의존성 인슐리노트로핀 폴리펩타이드 유사물질, 이의 약학적 조성물 및 응용 |
| EP2718315B1 (fr) | 2011-06-10 | 2017-12-27 | Novo Nordisk A/S | Dérivés de pramlintide |
| WO2013003449A2 (fr) | 2011-06-27 | 2013-01-03 | Phasebio Pharmaceuticals, Inc. | Méthodes de traitement par des agonistes de récepteur du glp-1 |
| JP6126097B2 (ja) | 2011-09-06 | 2017-05-10 | ノヴォ ノルディスク アー/エス | Glp−1誘導体 |
| JP6254146B2 (ja) | 2012-03-27 | 2017-12-27 | エヌジーエム バイオファーマシューティカルス,インコーポレーテッド | 代謝障害を治療するための組成物および方法 |
| CA2872314C (fr) | 2012-05-03 | 2021-08-31 | Zealand Pharma A/S | Composes agonistes doubles du gip-glp-1 et methodes |
| EP2846823B1 (fr) | 2012-05-08 | 2019-12-04 | Novo Nordisk A/S | Dérivés glp-1 double-acylatés |
| WO2013192310A1 (fr) | 2012-06-19 | 2013-12-27 | Massachusetts Institute Of Technology | Production à grande échelle et contrôle de dimension de nanoparticules par l'intermédiaire de microvortex régulés |
| SI2864350T1 (en) | 2012-06-21 | 2018-08-31 | Indiana University Research And Technology Corporation | GLUCAGON ANALOGUE ANALOGUE WITH ACTIVITY OF GIP RECEPTOR |
| ES2602486T3 (es) | 2012-06-21 | 2017-02-21 | Indiana University Research And Technology Corporation | Análogos de glucagón que muestran actividad de receptor de GIP |
| US20150344540A1 (en) | 2012-12-19 | 2015-12-03 | Novo Nordisk A/S | Novel glp-1 receptor agonists with cholesterol efflux activity |
| HUE035803T2 (en) | 2012-12-21 | 2018-05-28 | Sanofi Sa | Dual GLP1 / GIP or trigonal GLP1 / GIP / glucagon agonists |
| CA2902352A1 (fr) | 2013-03-14 | 2014-09-18 | Medimmune Limited | Co-agonistes pegyles du glucagon et de glp-1 pour le traitement de l'obesite |
| DK3004155T3 (da) | 2013-05-28 | 2022-01-03 | Takeda Pharmaceuticals Co | Peptidforbindelse |
| AU2014345570B2 (en) | 2013-11-06 | 2019-01-24 | Zealand Pharma A/S | Glucagon-GLP-1-GIP triple agonist compounds |
| TW201625668A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 作為胜肽性雙重glp-1/昇糖素受體激動劑之艾塞那肽-4衍生物 |
| JP2018012644A (ja) | 2014-11-26 | 2018-01-25 | 武田薬品工業株式会社 | ペプチド化合物 |
-
2014
- 2014-05-27 DK DK14729976.2T patent/DK3004155T3/da active
- 2014-05-27 EP EP14729976.2A patent/EP3004155B1/fr active Active
- 2014-05-27 WO PCT/JP2014/002772 patent/WO2014192284A1/fr not_active Ceased
- 2014-05-27 CA CA2908581A patent/CA2908581C/fr active Active
- 2014-05-27 AP AP2015008781A patent/AP2015008781A0/xx unknown
- 2014-05-27 MY MYPI2015703438A patent/MY172744A/en unknown
- 2014-05-27 PT PT147299762T patent/PT3004155T/pt unknown
- 2014-05-27 MX MX2015015464A patent/MX373436B/es active IP Right Grant
- 2014-05-27 US US14/780,579 patent/US10087229B2/en active Active
- 2014-05-27 SI SI201431933T patent/SI3004155T1/sl unknown
- 2014-05-27 GE GEAP201413984A patent/GEP201706762B/en unknown
- 2014-05-27 LT LTEPPCT/JP2014/002772T patent/LT3004155T/lt unknown
- 2014-05-27 AR ARP140102090A patent/AR096440A1/es active IP Right Grant
- 2014-05-27 UY UY0001035589A patent/UY35589A/es not_active Application Discontinuation
- 2014-05-27 PL PL14729976T patent/PL3004155T3/pl unknown
- 2014-05-27 EA EA201591891A patent/EA035813B1/ru unknown
- 2014-05-27 MX MX2019010531A patent/MX388826B/es unknown
- 2014-05-27 KR KR1020157032121A patent/KR102229051B1/ko active Active
- 2014-05-27 UA UAA201510946A patent/UA118558C2/uk unknown
- 2014-05-27 JP JP2015555470A patent/JP6429799B2/ja active Active
- 2014-05-27 MA MA38472A patent/MA38472B1/fr unknown
- 2014-05-27 EA EA202090593A patent/EA202090593A3/ru unknown
- 2014-05-27 CN CN201480026613.0A patent/CN105209485B/zh active Active
- 2014-05-27 AU AU2014272500A patent/AU2014272500B2/en active Active
- 2014-05-27 HU HUE14729976A patent/HUE057361T2/hu unknown
- 2014-05-27 HR HRP20212014TT patent/HRP20212014T1/hr unknown
- 2014-05-27 ES ES14729976T patent/ES2900744T3/es active Active
- 2014-05-27 US US14/287,514 patent/US9200051B2/en active Active
- 2014-05-27 PE PE2015002124A patent/PE20151770A1/es unknown
- 2014-05-27 TW TW103118374A patent/TWI638831B/zh active
- 2014-05-27 SG SG11201507934PA patent/SG11201507934PA/en unknown
- 2014-05-27 TN TN2015000451A patent/TN2015000451A1/en unknown
-
2015
- 2015-10-11 IL IL242005A patent/IL242005B/en active IP Right Grant
- 2015-10-13 CL CL2015003031A patent/CL2015003031A1/es unknown
- 2015-10-14 PH PH12015502391A patent/PH12015502391B1/en unknown
- 2015-10-15 DO DO2015000261A patent/DOP2015000261A/es unknown
- 2015-10-21 EC ECIEPI201544389A patent/ECSP15044389A/es unknown
-
2018
- 2018-06-12 JP JP2018111494A patent/JP6570705B2/ja active Active
-
2021
- 2021-12-15 CY CY20211101100T patent/CY1124790T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA38472A1 (fr) | Composé peptidique | |
| MA38390B1 (fr) | Composés tétrahydropyrrolothiazines | |
| BR112017006253A2 (pt) | novos compostos | |
| EA201590854A1 (ru) | Пиридин-2-амиды, пригодные в качестве агонистов каннабиноидного рецептора 2 | |
| EA201691982A1 (ru) | 5,6-дизамещенные пиридин-2-карбоксамиды в качестве агонистов каннабиноидных рецепторов | |
| MA37501B1 (fr) | Composés de pyrazole utilisés en tant qu'inhibiteurs de sglt1 | |
| AR095523A1 (es) | Derivados piridin-4-ilo | |
| EA201691983A1 (ru) | Пиридин-2-амиды, пригодные в качестве агонистов cb2 | |
| AR095097A1 (es) | Compuestos de fenoxietoxi | |
| EA201692270A1 (ru) | Производные нафтиридиндиона | |
| AR105821A1 (es) | COMPUESTOS ÚTILES PARA INHIBIR ROR-g-T | |
| AR100913A1 (es) | Síntesis de complejo de zinc-lisina a partir de cloruro de zinc | |
| MX2017006709A (es) | Agente para prevenir o mejorar sintomas causados por desequilibrio de las hormonas sexuales. | |
| SV2019005838A (es) | Derivado de triazolopirazinona útil como un inhibidor de pde1 humana | |
| MA39305A3 (fr) | Dérivés d'éthynyle | |
| NZ707308A (en) | Malononitrile compounds for controlling animal pests | |
| MA39108A1 (fr) | Nouveau composé pour le traitement de l'hypoglycémie sévère | |
| CL2018002422A1 (es) | Preparación que contiene agua de mar a la que se ha agregado un compuesto de potasio. | |
| DOP2017000016A (es) | Nueva sal de disoproxilo de tenofovir | |
| MA39756B1 (fr) | Nouveau sel de l'ivabradine et son procédé de préparation | |
| AR115865A2 (es) | Compuestos terapéuticos | |
| AR112111A1 (es) | Tetrahidropiridopirazinas moduladoras de receptores gpr6 | |
| AR095761A1 (es) | Compuestos de dihidropirido pirimidina | |
| AR104848A1 (es) | Derivados de ácido 2-oxo-1,3,8-triazaespiro[4.5]decan-3-il]carboxílico | |
| AR105475A1 (es) | Antagonistas del receptor de cgrp |